PACB Jan 2026 3.000 call
| Previous close | 0.9700 |
| Open | 0.9500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 3.00 |
| Expiry date | 2026-01-16 |
| Day's range | 0.9500 - 0.9700 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
PR NewswireAmbry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases
Ambry Genetics, a prominent leader in clinical genomic testing and a subsidiary of REALM IDx, Inc., along with PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced their companies' selection by the University of California, Irvine (UCI) and the GREGoR Consortium (Genomics Research to Elucidate the Genetics of Rare diseases) to support the Pediatric Mendelian Genomics Research Center (MGRC) program to better understand the underlying bi
Simply Wall St.Pacific Biosciences of California First Quarter 2024 Earnings: Misses Expectations
Pacific Biosciences of California ( NASDAQ:PACB ) First Quarter 2024 Results Key Financial Results Revenue: US$38.8m...
Insider MonkeyPacific Biosciences of California, Inc. (NASDAQ:PACB) Q1 2024 Earnings Call Transcript
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q1 2024 Earnings Call Transcript May 9, 2024 Pacific Biosciences of California, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello and welcome to the PacBio First Quarter 2024 Earnings Conference Call. All […]
